FirsthandHealth
medRxiv PreprintsInternational20 November 2026

Evaluation of Semaphorin 3G (SEMA3G) as a biofluid biomarker of cerebral amyloid angiopathy: evidence from neurodegenerative disease and memory clinic cohorts

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Introduction: Cerebral amyloid angiopathy (CAA) is characterised by amyloid-beta (A{beta}) deposition in cerebral vessels, and frequently co-occurs with Alzheimer's disease (AD). Diagnosis based on MRI-based Boston criteria is not definitive, and CAA biofluid biomarkers are needed. Semaphorin 3G (SEMA3G) was recently shown to be selectively enriched in CAA-affected vessels, and correlated with CAA severity. We therefore evaluated SEMA3G as a biofluid biomarker of CAA. Methods: SEMA3G profiles were examined across diagnoses in the Global Neurodegeneration Proteomics Consortium dataset (GNPC) in
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.